title: [Effect of valsartan on postprandial plasma inflammatory factors in patients with essential hypertension].
abstract: OBJECTIVE
  To explore the effect of valsartan on the concentrations of plasma inflammatory factors after a high-fat meal in patients with essential hypertension in very short time.
  
  
  METHODS
  Fifty hypertensive patients and 25 healthy controls were studied. Patients randomly accepted lacidipine 4 mg/d (lacidipine group) or valsartan 80 mg/d (valsartan group) for 1 week. The concentrations of plasma lipid profiles, high-sensitivity C-reactive protein (hsCRP) and soluble P-selectin were measured in fasting state and at 4 h after a single high-fat meal in all subjects at baseline and in patients after 1 week.
  
  
  RESULTS
  The concentrations of postprandial plasma hsCRP and soluble P-selectin significantly increased after a high-fat meal in patients (P < 0.05), as compared with those at fasting levels, but not in the controls. The postprandial plasma triglyceride concentrations significantly increased in the healthy controls (P < 0.05), but were lower than those in hypertensive patients (P < 0.01). Postprandial change in plasma concentration of triglyceride was significantly correlated with those of log (hsCRP) (r = 0.344)and soluble P-selectin (r = 0.432), respectively (n = 75, both P < 0.01). Lipids profiles did not change significantly after 1 week. There was no significant difference between the fasting and postprandial plasma concentrations of either hsCRP or soluble P-selectin in valsartan group, while the postprandial increments of inflammatory factors were still significant in the lacidipine group.
  
  
  CONCLUSIONS
  High-fat meal can induce postprandial inflammation response in patients with essential hypertension. Valsartan effectively attenuates this postprandial inflammation response within a very short time.
authors.affiliation: Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha 410011, China. feliuling@medmail.com.cn
authors.forename: Ling
authors.initials: L
authors.lastname: Liu
authors.forename: Shui-Ping
authors.initials: SP
authors.lastname: Zhao
authors.forename: Hong-Nian
authors.initials: HN
authors.lastname: Zhou
authors.forename: Dan-Yan
authors.initials: DY
authors.lastname: Xu
authors.forename: Ji-Xiang
authors.initials: JX
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism*; D004041:Dietary Fats / Q000009:adverse effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood*; D013777:Tetrazoles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D000959:Antihypertensive Agents; D004041:Dietary Fats; D019007:P-Selectin; D013777:Tetrazoles; D014280:Triglycerides; D000068756:Valsartan; D002097:C-Reactive Protein; D014633:Valine